Ado-trastuzumab emtansine is used for the treatment of patients with HER2-positive breast cancer.

Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death.

Ado-trastuzumab emtansine suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Ado-trastuzumab emtansine brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ALUNBRIG (brigatinib) tablets cost price in India.

The order for Ado-trastuzumab emtansine will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

KADCYLA™ (ado-trastuzumab emtansine) for injection, for intravenous use. Initial U.S. Approval: 2013

Generic Name: brigatinib

Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.

ado-trastuzumab emtansine for injection

Ado-trastuzumab emtansine for injection, for intravenous use is available.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Ado-trastuzumab emtansine suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KADCYLA (ado-trastuzumab emtansine) on prescription and Import License in Patient's Name only.

For overseas patients, Ado-trastuzumab emtansine can be made available in Send your enquiry to find KADCYLA (ado-trastuzumab emtansine) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Ado-trastuzumab emtansine.

For KADCYLA (ado-trastuzumab emtansine) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Genentech’s Kadcyla Wins Second FDA Approval for HER2-Positive Breast Cancer For More Details

Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer For More Details